LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

84.14 1.99

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

80.39

Максимум

84.66

Ключови измерители
By Trading Economics
Приходи	5.4M -48M
Продажби	6M 57M
EPS	-0.82
Марж на печалбата	-82.974
Служители	414
EBITDA	5.1M -43M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+63.55% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-650M 5.8B
Предишно отваряне	82.15
Предишно затваряне	84.14

Настроения в новините

By Acuity

25%

75%

56 / 350 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.03.2026 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Infosys Agrees to Acquire Stratus

25.03.2026 г., 23:58 ч. UTC

Печалби

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25.03.2026 г., 23:58 ч. UTC

Печалби

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25.03.2026 г., 23:57 ч. UTC

Печалби

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25.03.2026 г., 23:57 ч. UTC

Печалби

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25.03.2026 г., 23:56 ч. UTC

Печалби

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25.03.2026 г., 23:56 ч. UTC

Печалби

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25.03.2026 г., 23:41 ч. UTC

Печалби

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25.03.2026 г., 23:34 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Declines on Possible Technical Correction -- Market Talk

25.03.2026 г., 22:08 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.03.2026 г., 22:08 ч. UTC

Пазарно говорене

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25.03.2026 г., 22:07 ч. UTC

Печалби

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25.03.2026 г., 22:07 ч. UTC

Печалби

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25.03.2026 г., 22:07 ч. UTC

Печалби

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25.03.2026 г., 22:07 ч. UTC

Печалби

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25.03.2026 г., 22:07 ч. UTC

Печалби

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25.03.2026 г., 21:58 ч. UTC

Пазарно говорене

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25.03.2026 г., 21:37 ч. UTC

Пазарно говорене

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25.03.2026 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25.03.2026 г., 21:13 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25.03.2026 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

25.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

25.03.2026 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25.03.2026 г., 20:31 ч. UTC

Печалби

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25.03.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25.03.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25.03.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25.03.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

63.55% нагоре

12-месечна прогноза

Среден 135.08 USD 63.55%

Висок 152 USD

Нисък 105 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

56 / 350 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.